Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyglycolated urate oxidase is an investigational PEGylated (polyethylene glycol-conjugated) form of the enzyme urate oxidase (uricase), currently under development by The Affiliated Hospital of Qingdao University. As a recombinant enzyme, it catalyzes the conversion of uric acid into allantoin, a highly soluble metabolite that is readily excreted by the kidneys, thereby lowering serum urate levels. It is primarily being investigated for the treatment of hyperuricemia. The drug is undergoing Phase 1 clinical evaluation (NCT05226013) to determine its safety, tolerability, pharmacokinetics, and immunogenicity in both healthy individuals and patients with elevated uric acid.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyglycolated urate oxidase.